FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 683 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Interactive App Improves Colorectal Cancer Screening Rates April 9, 2018 Meteorologist Uses Sign Language To Tell All Of Her Weather Forecasts February 12, 2022 If You Let It, Nursing Will Change Your Life May 24, 2021 The Childhood Cancer Data Initiative: Transforming the Pediatric Cancer Landscape through... August 15, 2019 Load more HOT NEWS Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally... Rare Cancers Forum 2026: ESMO Leads European Efforts to Turn Evidence... Skull Implant Delivers Drugs with Precision, Offering Hope for Parkinson’s, Cancer,... Getting Help for Sexual Health Problems When You Have Head and...
